Current approaches in treatment of triple-negative breast cancer
- PMID: 26175926
- PMCID: PMC4493381
- DOI: 10.7497/j.issn.2095-3941.2015.0030
Current approaches in treatment of triple-negative breast cancer
Abstract
Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting.
Keywords: Breast cancer; HER2; triple-negative.
Conflict of interest statement
No potential conflicts of interest are disclosed.
References
-
- American Cancer Society. Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society; 2010.
-
- Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360. - PubMed
-
- Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26:2568-2581. - PubMed
-
- Crutcher CL, Cornwell LB, Chagpar AB. Effect of triple-negative status on surgical decision making. ASCO 2010.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous